Search research articles
Contact Us
Filters
Showing results (421-430 of 438) with videos related to
Page
of 44
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Future Oncology (London, England)
|
November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine
|
June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
David P Carbone, Martin Reck, Luis Paz-Ares, et al.
The New England Journal of Medicine
|
October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine
|
October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Nature Medicine
|
January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
JTO Clinical and Research Reports
|
February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
Giannis Mountzios, David Planchard, Giulio Metro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
Petros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Clinical & Experimental Metastasis
|
July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)
Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Page
of 44
Search research articles
Search
Showing results (421-430 of 438) with videos related to
Sort By:
Page
of 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Future Oncology (London, England)
|
November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine
|
June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
David P Carbone, Martin Reck, Luis Paz-Ares, et al.
The New England Journal of Medicine
|
October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
The New England Journal of Medicine
|
October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J Antonia, Augusto Villegas, Davey Daniel, et al.
Nature Medicine
|
January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
JTO Clinical and Research Reports
|
February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
Giannis Mountzios, David Planchard, Giulio Metro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
Petros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Clinical & Experimental Metastasis
|
July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)
Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Page
of 44